- Home
- TEI vs SERA Comparison
TEI vs SERA Comparison
Compare TEI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TEI | SERA |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.9M | 75.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TEI | SERA |
|---|---|---|
| Price | $6.25 | $1.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 136.1K | 38.3K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $5.48 | $1.37 |
| 52 Week High | $7.00 | $4.09 |
Technical Indicators
Market Signals| Indicator | TEI | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 41.11 |
| Support Level | $6.19 | $1.67 |
| Resistance Level | $6.48 | $2.03 |
| Average True Range (ATR) | 0.13 | 0.20 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 39.51 | 30.91 |
Price Performance
Historical ComparisonAbout TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.